



Press release from Emotra AB (publ)
Göteborg, October 8, 2020

Claes Holmberg, the chairman of the board, intends to convert his subscription warrants

Claes Holmberg, the chairman of the board of Emotra AB (“Emotra” or “the Company”) has notified that he intends to exercise his right to convert subscription warrants in connection with the second phase of Emotra’s rights issue.

Claes Holmberg, the chairman of the board of Emotra, says:

“In my opinion, carrying out clinical studies to confirm the connection between hyporeactivity, which can be identified with EDOR®, and an increased risk of depression relapse is a wise choice. I have never held any doubts about exercising all of my subscription warrants to purchase more shares in the Company.”

As notified on October 6, 2020, the exercise price for the subscription warrants has been set to 0.40 SEK per share. One (1) subscription warrant gives the owner the right to purchase one (1) new share in Emotra in the period October 9 to 23 inclusive, 2020.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail:

daniel@emotra.se

Fel! Hittar inte referenskälla.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1,
SE- 431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se